Strata Critical Medical SRTA
- Market cap
- $378.6M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $256M
- +49% on a year ago
- Net margin
- 15.7%
- Free cash flow yield
- −12.8%
Strata Critical Medical trades at 1.5× sales. Revenue was $256M over the last twelve months, up 49% on a year earlier with a 16% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $71.4M+56% | $47.5M+25% | $51.5M+14% | $67.9M+11% | $36.1M−50% | $54.4M+15% | $35.9M−30% | $45.1M−34% | $49.3M+37% | $66.8M+23% | $67.4M+87% | $72.5M+61% | |
| Cost of revenue | $55.9M+53% | $38.5M+16% | $41.4M+9% | $51.6M+2% | $28.6M−49% | $41.8M+9% | $28.9M−30% | $36.1M−30% | $37.7M+32% | $55.1M+32% | $53.3M+84% | $57.3M+59% |
| Gross profit | $15.6M+68% | $9M+81% | $10.1M+42% | $16.4M+58% | $7.5M−52% | $12.6M+40% | $7.1M−30% | $9M−45% | $11.6M+55% | $11.7M−7% | $14.1M+100% | $15.2M+69% |
| R&D | $1.1M−47% | $988K−39% | $670K−40% | $971K−33% | $417K−61% | $743K−25% | $812K+21% | $915K−6% | $453K+9% | n/a | n/a | n/a |
| SG&A | $22M+24% | $43.7M+90% | $19.3M+3% | $27.5M+30% | $14.2M−35% | $20.2M−54% | $12.3M−36% | $13.3M−52% | $16.8M+18% | $16.8M−17% | $15.6M+27% | $14M+5% |
| −$7.4M−29% | −$35.6M+81% | −$9.9M−23% | −$12.1M−1% | −$7.1M−5% | −$8.4M−77% | −$5.7M−42% | −$4.6M−62% | −$5.6M−21% | −$6.4M−24% | −$3M−48% | −$5.4M+17% | |
| Pre-tax income | $418K | −$35M+115% | −$4.3M−58% | −$11.3M−11% | −$5.6M | −$9.9M−72% | −$1.6M−63% | −$3.4M−70% | −$9.7M+72% | −$5.4M−46% | $2.4M | −$10.5M+209% |
| $129K+130% | −$1M+24% | −$84K−57% | $52K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | $289K | −$33.9M+120% | −$4.2M−59% | −$11.3M−7% | −$2M | −$9.8M−71% | −$3.5M−18% | −$3.7M−67% | $57.4M | −$8.8M−10% | $2.2M | −$10.5M+181% |
| $0.00 | −$0.45+105% | −$0.06−57% | −$0.15−12% | −$0.03 | −$0.12−73% | −$0.04−33% | −$0.05−67% | $0.70 | −$0.10−17% | $0.03 | −$0.12+140% | |
| 81M+13% | 74.8M+4% | 75.8M+5% | 77.6M+6% | 78M−4% | 78.5M+5% | 79.9M+5% | 81.3M+5% | 82.5M+6% | 84.7M+8% | 90.2M+13% | 86.2M+6% |
Gross profit: 18 periods, Q4 FY20 to Q3 FY25: not printed by the filing, worked out from its own lines.
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Travel Services nearest Strata Critical Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SRTAStrata Critical Medical | $378.6M | n/m | 10.6× | 1.5× | +49% | 15.7% | |
| VRRMVERRA MOBILITY | $407.4M | 11.2× | 44.2× | 0.4× | +6% | 3.8% | |
| PANLPangaea Logistics Solutions | $495M | 10.1× | 9.2× | 0.7× | +23% | 6.7% | |
| GNKGenco Shipping & Trading | $1.1B | 27.2× | 13.0× | 2.4× | +26% | 9.1% | |
| LPGDorian LPG | $2.2B | 6.8× | 7.0× | 3.7× | +81% | 55.0% | |
| ABMABM Industries | $3.2B | 19.5× | 21.9× | 0.3× | +6% | 1.8% | |
| Peer median | $1.1B | 11.2× | 13.0× | 0.7× | +23% | 6.7% |
Investors who own it
Investors we follow who held Strata Critical Medical at the end of Jun 30, 2026, from their 13F filings.
- Dan LoebThird Point0.6% of portfolio
- Cathie WoodARK Investment Management0.1% of portfoliotrimmed
More on Strata Critical Medical
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #9of 332Consumer cyclical stocks with the fastest revenue growth
- #3of 23Travel stocks with the fastest revenue growth
- #7of 23Travel stocks with the highest profit margins
- #9of 24Travel stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Travel Services
- Sector
- Consumer Cyclical
Valuation data, not investment advice. Prices as of .